Globe Newswire
- An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacy
- SYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses ≥ 1.2mg/Kg
- No dose limiting toxicities (DLTs) have been observed to date in doses up to and including 4.5 mg/Kg (cohort 7)
- Three cases of skin rash (including one grade 3) and one case of grade 1 neuropathy seen to date; all... (continue reading...)
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment
Initial data from Phase 0/1 “trigger” (“window of opportunity”) investigator-sponsored trial demonstrated BDTX-1535 achieved clinically meaningful drug levels in brain tumor tissue
CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc.... (continue reading...)
Media Release
COPENHAGEN, Denmark, and MAINZ, Germany; June 1, 2024
- Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival (mOS) of 17.5 months in patients with previously treated PD-L1-positive mNSCLC treated with combination of acasunlimab with pembrolizumab every six weeks
- Data from this ongoing Phase 2 study to inform the planned pivotal Phase 3 trial, which is expected to start before the end... (continue reading...)
NASSAU, The Bahamas, June 01, 2024 (GLOBE NEWSWIRE) -- OKX, a leading crypto exchange by trading volume and a leading Web3 technology company, has issued updates for June 1, 2024.
OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures ListingIn a continuous effort to enhance market liquidity and mitigate risks, OKX has announced that it will be making adjustments to the position tiers of its TURBO/USDT perpetual futures listing.
This action... (continue reading...)
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy -
- Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete response -
- Monotherapy recommended dose for expansion selected and expansion arms open for enrollment -
- Preliminary data on WTX-124 administered to patients in combination with... (continue reading...)
More Globe Newswire
View Older Stories-
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
-
FSLY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Fastly, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
-
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
-
OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
-
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
-
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
-
CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes
-
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
-
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
-
ENPH INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Enphase Energy, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
-
VENTYX SHAREHOLDER REMINDER: BFA Law Reminds Ventyx Biosciences, Inc. (NASDAQ: VTYX) Shareholders to Contact the Firm About Ongoing Investigation
-
SQSP (NYSE) REMINDER: BFA Law Reminds Squarespace Shareholders to Inquire About Ongoing Investigation into the $44 Buyout Offer
-
SPT (NYSE) FRAUD ALERT: Sprout Social, Inc. Investors who Lost Money when Stock Plummeted 40% are Encouraged to Contact BFA Law about Upcoming Deadline
-
PATH (NYSE) INVESTOR ALERT: UiPath, Inc. Investigated for Securities Fraud After 34% Stock Drop, Contact BFA Law if You Suffered Losses
-
CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation into the $45 Merger Offer
-
CAE (NYSE) INVESTOR ALERT: CAE, Inc. Investigated for Securities Fraud from Impairment Charges, Contact BFA Law if You Suffered Losses
-
BIIB (NASDAQ) FRAUD ALERT: Biogen Inc. Investors who Lost Money are Encouraged to Contact BFA Law about Upcoming Legal Deadline
-
NIO Inc. Provides May 2024 Delivery Update
-
XPENG Announces Vehicle Delivery Results for May 2024
-
Subsea7 awarded four PLSV contracts in Brazil
-
Swiss Properties Invest has finalised the acquisition of an attractive commercial property in Koblenz in the Canton of Aargau
-
Flash News: OKX Lists WLD/USDC Spot Trading Pair
-
Li Auto Inc. May 2024 Delivery Update
-
Cielo Announces Final Closing of Private Placement of Convertible Debenture Units
-
2024 Canadian Screen Award Winners Announced
-
HIRERIGHT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against HireRight Holdings Corporation and Encourages Investors to Contact the Firm
-
TORO ALERT: Bragar Eagel & Squire, P.C. is Investigating The Toro Company on Behalf of Toro Stockholders and Encourages Investors to Contact the Firm
-
VERADIGM ALERT: Bragar Eagel & Squire, P.C. is Investigating Veradigm Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
-
DIRECT DIGITAL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Direct Digital Holdings, Inc. and Encourages Investors to Contact the Firm
-
CHECKPOINT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Checkpoint Therapeutics, Inc. and Encourages Investors to Contact the Firm
-
BIIB Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Biogen Inc. Class Action
-
CMBM Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Cambium Networks Corporation Class Action
-
DRCT Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Direct Digital Holdings, Inc. Class Action
-
Pasinex Announces Filing of 2023 Annual Financial Results
-
MAG Silver Announces Filing of Final Base Shelf Prospectus
-
The Boston Beer Company Statement on Company Sale Speculation
-
Mayfair Gold Announces that Certain Employees May Withdraw Notices of Termination under Change of Control to Continue Employment with the Company
-
Kruger Products unionized employees on strike at Crabtree plant and Joliette warehouse
-
Carbon Streaming Announces Board and Management Changes
-
Lynch Carpenter Investigates Claims in Sav-RX Data Breach
-
Lynch Carpenter Investigates Claims in Ticketmaster Data Breach
-
Northfield Capital Announces Grant of Options
-
Eldorado Gold Publishes 2023 Sustainability Report; Our Sustainability Framework in Action
-
Mainz Biomed Reports Results of 2024 Annual General Meeting
-
Forge First Asset Management Inc. Announces Changes to Investment Strategies
-
FLINT extends maturity date of Credit Facility, Term Loans and Senior Secured Debentures
-
Prospect Floating Rate and Alternative Income Fund Announces an Increased 7.5% Annualized Total Cash Distribution Percentage Rate on Net Asset Value for May 2024 and Announces a Registered Multi-Class